Digest Network Come funziona
Network
/
Società
De
Non verificato

Debiopharm

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaOncologiaSalute

19 comunicati stampa

Guarda tutti i comunicati
04/12/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Sanità
Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment
Fonte
Debiopharm
Emittente
Business Wire
1.00
0
18/11/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program
Fonte
Debiopharm
Emittente
Business Wire
1.00
0
06/11/2025
Industria
Infanzia
Biotecnologia
Salute
Farmaceutica
Oncologia
Scienza
Famiglia
Vetrine/Shopping
Medicina - Varie
Debiopharm Takes a Step Forward for Children With CPP: Enrollment Completion for the Phase III Trial Evaluating the First Ever Yearly Injectable Triptorelin Formulation
Fonte
Debiopharm
Emittente
Business Wire
1.00
0
30/10/2025
Tecnica
Scienza
Biotecnologia
Salute
Farmaceutica
Oncologia
Mercato del lavoro
Debiopharm Forges AI-powered Alliance With NetTargets to Pioneer Dual-payload ADCs Against Drug-resistant Cancers
Fonte
Debiopharm
Emittente
Business Wire
1.00
0
30/09/2025
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Oncologia
Industria
Debiopharm Licenses SunRock Biopharma’s Anti-HER3/HER2 Antibody to Explore the Full Potential of Bispecific ADC Debio 2512
Fonte
Debiopharm
Emittente
Business Wire
1.00
0
26/08/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Industria
Debiopharm Pushes the Boundaries of Innovation in Antibiotic Development Against Gonorrhea with First-In-Human Debio 1453 Trial
Fonte
Debiopharm
Emittente
Business Wire
1.00
0
16/06/2025
Scienza
Medicina - Varie
Biologia
Biotecnologia
Salute
Farmaceutica
Oncologia
Industria
Debiopharm’s ADC Research Gains Momentum With Launch of First-in-human Trial Assessing Debio 1562M in Acute Myeloid Leukemia Patients
Fonte
Debiopharm
Emittente
Business Wire
1.00
0
29/05/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Debiopharm Ignites Oncology Innovation With Clinical and Translational Data on Debio 0123 at the 2025 ASCO Annual Meeting in Chicago
Fonte
Debiopharm
Emittente
Business Wire
1.00
0
28/05/2025
Scienza
HIV, AIDS e malattie autoimmuni
Assistenza all'Infanzia
Medicina - Varie
Biotecnologia
Farmaceutica
Vetrine/Shopping
Salute
Oncologia
Industria
CARB-X Grants Debiopharm an Additional $12.3 Million to Advance Development of Novel Antibiotic Against Gonorrhea
Fonte
Debiopharm
Emittente
Business Wire
1.00
0
22/04/2025
Finanza
Eventi
Fiere
Computer grafica 3D
Industria
Tecnica
Biologia
Medicina nucleare
Farmaceutica
Oncologia
Biotecnologia
Medicina - Varie
Scienza
Salute
Debiopharm to Reveal Insights From Their ADC, DDR Inhibitor, and Antibody Conjugation Technology Research at the 2025 AACR Conference in Chicago
Fonte
Debiopharm
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0